New Alzheimer’s drug AR1001 shows promising results in Phase 3 clinical trial
Over a one year trial, the new Alzheimer’s drug AR1001 slowed decline in memory and thinking problems by nearly a third.
Dr Richard Oakley, Associate Director for Research and Innovation at Alzheimer’s Society, said:
'These topline results are an exciting sign that we could have a totally new treatment for early Alzheimer’s disease that tackles its causes, not just its symptoms.
It's fantastic to see research and clinical trials unlocking promising new ways to target Alzheimer's disease.
'AR1001 takes a novel approach, relaxing blood vessels to increase blood flow to the brain. And unlike other disease-modifying treatments that have shown benefit in late-stage trials, it is taken as a once-a-day tablet, which could make treatment simpler.
Drug trial results for AR1001 show some promising effects on memory and thinking
'Over the year of the trial, this drug was able to effectively slow down people’s decline in memory and thinking by nearly a third, and the side effects reported were mostly mild to moderate.
'However, the drug doesn’t seem to be as effective for people taking other drugs for Alzheimer’s symptoms, so this needs further investigation.
AR1001 drug is not yet available in the UK
'AR1001 is from the same family of medicines as Viagra, but it is being developed specifically for Alzheimer’s disease. People should not take Viagra to try to treat Alzheimer’s.
'It’s also important to note AR1001 is not yet available to the public and will need to be assessed and approved by UK regulatory bodies before it could be offered in the UK.
The importance of early and accurate dementia diagnosis
'Research is making huge progress and will beat dementia – and as more potential treatments emerge, it’s more important than ever that people get an early and accurate dementia diagnosis so they can benefit from them.
'We look forward to seeing the full results from this trial and how this drug progresses.'
Take part in dementia research
Research is only possible thanks to the people who participate. If you would like to get involved in dementia research, we can support you.